Oncolytics Biotech Inc T.ONC

Alternate Symbol(s): ONCY

Healthcare Biotechnology

Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to registration-enabling clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.

TSX:ONC - Post by User

Oncolytics Biotech Inc > City of Hope Developes CAR-T Cell Therapy in Ovarian Cancer

<< Previous

Bullboard Posts

Next >>

Comment by jimsenioron Aug 11, 2023 11:05am

148 Views

Post# 35583845

RE: City of Hope Developes CAR-T Cell Therapy in Ovarian Cancer

@Noteable. Very Interesting. For information only. City of Hope Medical Center is a collaborator on NCT03605719. That is the MM trial with pela, carfilzomib, opdivo et al. Hofmeister.

News on the CAR T front woud be nice. I still think pela is very much in the hunt, but there is a lot happening on the oncology front, and we do not want to be left behind.

GO

<< Previous

Bullboard Posts

Next >>

Sirios Resource discovers visible gold in Quebec